Company Profiles

driven by the PitchBook Platform

Bicycle Therapeutics

Description

Developer of first in class medicines created to treat cancer and other debilitating diseases. The company's first in class medicines includes bicyclic peptides that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis, exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities.

2009

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$51.7M

Latest Deal Amount

$93.9M

Total Amount Raised

Description

Developer of first in class medicines created to treat cancer and other debilitating diseases. The company's first in class medicines includes bicyclic peptides that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis, exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities.

Website:

www.bicycletherapeutics.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Meditrina Building Babraham Research Campus Cambridge CB22 3ATEngland +44 (0)12 2326 1503
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Bicycle Therapeutics's full profile, request a free trial.

Bicycle Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Bicycle Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Bicycle Therapeutics Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Astellas Venture ManagementCorporate Venture CapitalMinority000 0000000 0000
Atlas VentureVenture CapitalMinority000 0000000 0000
Cambridge Innovation CapitalVenture CapitalMinority000 0000000 0000
Longwood FundVenture CapitalMinority000 0000000 0000
Novartis Venture FundCorporate Venture CapitalMinority000 0000000 0000
Astellas Venture Management Corporate Venture Capital
Atlas Venture Venture Capital
Cambridge Innovation Capital Venture Capital
Longwood Fund Venture Capital
Novartis Venture Fund Corporate Venture Capital

Bicycle Therapeutics Executive Team (9)

NameTitleBoard
Seat
Contact
Info
Kevin Lee Ph.DChief Executive Officer & Board Member
Rosamond DeeganChief Business Officer & President
Nick Keen Ph.DChief Scientific Officer
Alan Watt Ph.DInterim CSO and Head of Therapeutics
Christian Heinis Ph.DScientific Founder
Kevin Lee Ph.D Chief Executive Officer & Board Member
Rosamond Deegan Chief Business Officer & President
Nick Keen Ph.D Chief Scientific Officer
Alan Watt Ph.D Interim CSO and Head of Therapeutics
Christian Heinis Ph.D Scientific Founder

Bicycle Therapeutics Board Members (11)

NameRepresentingRoleSinceContact
Info
Anja König Ph.DNovartis Venture FundCo-Managing Director000 0000
Catherine BinghamSV Health InvestorsManaging Partner, Biotechnology000 0000
Christopher Shen MDVertex Ventures HCManaging Director000 0000
Deborah Harland Ph.DSR OnePartner000 0000
Gregory Winter Ph.DBicycle TherapeuticsCo-Founder & Board Member000 0000
Anja König Ph.D Co-Managing Director Novartis Venture Fund
Catherine Bingham Managing Partner, Biotechnology SV Health Investors
Christopher Shen MD Managing Director Vertex Ventures HC
Deborah Harland Ph.D Partner SR One
Gregory Winter Ph.D Co-Founder & Board Member Bicycle Therapeutics
Request full access to PitchBook